Achieve Life Sciences, Inc. (NASDAQ: ACHV)

Achieve Life Sciences, Inc., or ACHV, is a clinical-stage pharmaceutical company operating in the healthcare industry, with a specific focus on the development and commercialization of cytisinicline for the treatment of nicotine addiction and smoking cessation. The company is committed to addressing the global epidemic of tobacco use, which remains the leading cause of preventable disease and death worldwide.

ACHV's main business activities revolve around the development of cytisinicline, a product candidate that has shown robust efficacy and minimal frequency of side effects in two randomized, placebo-controlled Phase 3 studies. The company has an exclusive license and supply agreement with Sopharma AD, a pharmaceutical company, for the development and commercialization of cytisinicline outside of Sopharma's territories.

The company generates revenue primarily through the development of cytisinicline. Its primary product is a treatment for smoking cessation, and it has also begun developing cytisinicline as a treatment for nicotine e-cigarette cessation. The company's customer base includes pharmaceutical companies and healthcare providers who are interested in using cytisinicline as a treatment for nicotine addiction and smoking cessation.

ACHV's position within the industry is that of a small, clinical-stage pharmaceutical company with a focus on developing cytisinicline as a treatment for nicotine addiction and smoking cessation. The company is positioned to compete with other pharmaceutical companies that are developing treatments for nicotine addiction and smoking cessation. ACHV's competitive advantage lies in the unique mechanism of action of cytisinicline, which has been shown to reduce nicotine cravings, withdrawal symptoms, and reward and satisfaction associated with smoking. The company's product candidate has also demonstrated a favorable safety profile, with minimal frequency of side effects in clinical trials.

The company's regulatory efforts have made significant progress, including the filing of an Investigational New Drug (IND) application with the FDA for the evaluation of cytisinicline as a treatment for smoking cessation. The company has also held several meetings with the FDA and has received guidance on its Phase 3 clinical program. ACHV plans to submit an NDA to the FDA in the first half of 2025.

In terms of its product and service offerings, ACHV's primary product is cytisinicline, which is being developed as a treatment for smoking cessation and nicotine e-cigarette cessation. The company has completed two Phase 3 clinical trials for smoking cessation, which demonstrated a statistically significant reduction in daily smoking and a significant improvement in abstinence rates compared to placebo. The 3 mg TID dosing regimen showed the best overall safety and efficacy profile. Additionally, the company has completed a Phase 2 clinical trial for nicotine e-cigarette cessation, which showed a statistically significant benefit in vaping cessation rates compared to placebo. The company plans to request an end-of-Phase 2 meeting with the FDA to discuss a potential Phase 3 program for future supplemental NDA submission.